Our data also indicated that the predictive power of PD-L1 expression levels on tumor cells for immunotherapy efficacy was compromised, with no significant differences in the abundance of pan-CK+PD-L1+ cells between responders and non-responders (Table S5). The gene discussed is CD274; the disease is neoplasm.